We integrate computational power and biology to accelerate the discovery of life-transforming RNAi medicines. We focus on understanding human biological complexity to design better therapies for patients.
Presentation which accompanies the release of our Final Results for year ended 31 January 2022.
Presentation which accompanies the release of our Interim Results for six months ended 31 July 2021 and successful RNAi Platform Development.
Proactive Interview: Results demonstrating significant progress on our RNAi platform
e-therapeutics plc's (LON:ETX) CEO Ali Mortazavi talks to Proactive London about their six-month results and successful lab testing of its lead technology.
Proactive Interview: OTCQX Launch of Trading and RNAi Platform Progress
e-therapeutics plc's CEO Ali Mortazavi joins Proactive London after the recent launch of trading on the OTCQX Best Market under the ticker symbol ETXPF.
Proactive ONE2ONE Virtual Investors Forum
e-therapeutics plc's CEO Ali Mortazavi presenting at the Proactive One2One Virtual Forum, 15 July 2021.
e-therapeutics plc's CEO Ali Mortazavi presenting at the Proactive One2One Virtual Forum, 25 February 2021
Downloadable slides from this presentation are available here.
Shares Magazine Investor Evening Presentation
CEO and Chairman, Ali Mortazavi presenting at the Shares Magazine Investors Evening sponsored by A J Bell, 17 February 2021.
Shares investor webinar with CEO Ali Mortazavi
Ali Mortazavi presents a Company overview at a Shares investor evening sponsored by A J Bell.